James G. Hodge, Jr., J.D., LL.M., serves as the section editor for Public Health and the Law. He is Professor of Public Health Law and Ethics; Director, Center for Public Health Law and Policy (CPHLP), Sandra Day O'Connor College of Law, Arizona State University (ASU)
Over two decades, Americans across all socioeconomic groups have been adversely impacted by misuse of prescription and illicit opioids.Reference Joynt1 Several hundred thousand persons have died since 2001.2 Nearly 130 Americans perish on average each day abusing opioids. Millions more struggle annually with morbidity arising from their opioid use disorders (OUDs). Might 2019 be the year in which these horrendous impacts finally plateau? Initial surveillance reports based on 2018 data suggest that mortality rates stemming from America's worst public health emergency may have declined from 2017.3 Continued efforts across public and private sectors to seek emergency measures, tamp down access to prescription opioids, control illicit supplies, provide rapid treatments, and develop palliative substitutes are purposeful. Like the epidemic itself, however, existing interventions are getting old. Collectively, they may be insufficient to level the curve of public health repercussions.
Effectively addressing opioid misuse requires massive uptake of innovations in law and policy that exceed standard approaches. We proffer below a series of interventions at work or under consideration nationally or regionally to (1) immediately reverse opioid-related overdoses and deaths; and (2) avert negative future impacts.
Preventive Incentives
In other types of emergencies, public health interventions are freely distributed or heavily incentivized. During infectious disease outbreaks, for example, emergency laws support providing communities with no-cost vaccinations. After terrorism events or natural disasters, compensation funds are created legally to pay emergency victims for their losses. To the extent these incentives improve public health outcomes, they should be offered increasingly in response to the opioid emergency. Patients with acute pain opting out of opioid prescriptions, for example, should earn a rebate from their insurer. Prescription opioid collections should include cash buy backs or distributions of gift cards as incentives. Opioid abusers should be offered medication-assisted treatments (MATs) with no out-of-pocket costs. To any degree these initiatives derail persons from misusing or dying from opioids, they more than sustain their costs of implementation.
Supervised Injection Facilities (SIFs)
SIFs are a proven harm-reduction strategy to prevent opioid-related overdoses and deaths. They provide a safe place for patrons to use illicit drugs in a clean environment with immediate access to emergency medical services. Since their introduction in Switzerland in 1986, considerable research abroad illustrates SIFs' efficacy in obviating overdose fatalities, reducing public injections and discarded syringes, decreasing HIV infection rates, and linking patrons to addiction treatment.4 One study of a clandestine SIF operating in the U.S. since 2014 revealed similar results.Reference Kral and Davidson5
Multiple U.S. jurisdictions are interested in openly operating SIFs, but heavy-handed interpretations of laws and policies present real barriers. Multiple states refuse to support local SIF proposals. The Department of Justice (DOJ) asserted that SIFs are unlawful. On February 7, 2019, it sued to stop an SIF from opening in Philadelphia, alleging multiple violations of the federal Controlled Substances Act.6 DOJ is misguided. SIFs should be viewed as significant public health innovations, and not like crack houses subject to prosecution.
Prescription Limitations Across States
Americans remain awash in a sea of prescription opioids. In 2017, the average American patient received 3.4 opioid prescriptions, each lasting 18 days.7 Strict limitations on first-time opioid prescriptions should be adopted nationally. The Centers for Disease Control and Prevention (CDC) recommends in its Opioid Prescribing Guidelines that scrips be limited to the shortest duration possible (ideally 3 days or less).Reference Dowell8 The likelihood of long-term use increases markedly in the first days of a prescription.Reference Shah9 As of October 2018, 33 states had enacted legislation providing a limit or guidance requirement for opioid prescriptions.10 Massachusetts implemented the first limit in 2016 with a 7-day prescription maximum for first-time opioid “naïve” patients. In 2018, Florida restricted initial opioid prescriptions for acute pain to just 3 days in most cases; a 7-day supply is permitted only if a provider determines it is medically necessary. In addition to restricting prescription lengths, 5 states also limit the dosage of opioids allowed per day (e.g., morphine milligram equivalents). These state laws can dramatically reduce the number of opioids in circulation and lessen opportunities for long-term exposure.
Secondary Prescription Restrictions
Initial opioid prescribing rates are declining, but overprescribing through secondary prescriptions is still rampant. To tamp down this trend, all patients should have to submit to risk aversion educational training before receiving a prescription, akin to driver's license examinations. Additionally, medical providers responsible for doling out opioids or overseeing patient use should be required to complete MAT training as a condition of licensure. Providers should limit prescribing opioids for acute or chronic pain, choosing instead to rely on palliative care (e.g., over-the-counter medications, physical therapy) where effective. Insurers encourage alternative treatments by refusing to pay for prescriptions of OxyContin.Reference Farmer11 Clear guidelines centered on coordinated provider, patient, and insurer efforts can reduce secondary prescriptions and resulting opioid misuse.
Limited Access for Minors
Restricting minors' access to prescription opioids can prevent new generations from opioid addiction. Nationally, minors should not be prescribed opioids for acute pain, subject to exceptions (e.g., terminal or cancer patients, patients undergoing intense surgeries or with chronic injuries). As with adults, several states have legislatively limited the number of days allowed for initial prescriptions of opioids to minors. The Food and Drug Administration (FDA) requires prescription opioid cough and cold medicine labels to expressly indicate their use is limited to adults.12 Reducing minors' access to opioids includes targeting dentists who write the majority of opioid prescriptions for 10-19 year-olds.13 The American Dental Association's newly implemented opioid policy supports continuing education, legal limits on opioid dosage and duration, and referrals to existing prescription drug monitoring programs.14
Widespread Naloxone Access
As the opioid epidemic shifts toward American's increasing use of highly potent, illicit opioids, rapid access to naloxone, a drug used to reverse overdose effects, is crucial. Forty-six states have issued standing orders authorizing pharmacists to dispense naloxone without a prescription. Multiple states (AK, AZ, FL, MD, PA) have declared emergencies to allow first responders to carry and distribute naloxone.Reference Gostin15 Widespread access to naloxone, however, is still limited given high costs and low consumer awareness. FDA recently approved selling Narcan®, an easily administered naloxone nasal spray, over the counter (“OTC”). It is also debating whether to mandate distribution of naloxone with opioid prescriptions.16 Veterans Affairs hospitals stock naloxone in their automated external defibrillator cabinets for rapid overdose responses.Reference Bebinger17 Rhode Island stations Naloxboxes® across the state. Additional efforts to facilitate naloxone access in real time will save lives, allowing at-risk persons the chance to receive treatments later.
Emerging Litigation Themes
Thousands of lawsuits filed against opioid manufacturers, distributors, pharmacies, hospitals, doctors, and others reveal the potential for massive retribution for opioid's horrific impacts. Federal district court Judge Dan Aaron in Cleveland, Ohio has accepted oversight of thousands of opioid cases consolidated from around the country.Reference Hoffman18 Primary litigation themes focus on (1) fraudulent claims and misleading marketing that minimized patients' risks of addiction; and (2) unscrupulous distribution of millions of doses of opioids through doctors and pharmacies. Additional theories of liability have also emerged. The Navajo Nation alleges that Purdue Pharma's® aggressive marketing practices of OxyContin® constitute a public nuisance, an unlawful conspiracy, and federal racketeering.19 Several counties in West Virginia have sued the Joint Commission, which oversees hospitals nationally, for its role in promoting palliative treatments among patients.Reference Ward20 Federal judges in Ohio and Tennessee have enjoined multiple pharma entities to stop distributing all opioids due to alleged violations.Reference Mattise21 The sheer volume, breadth, and diversity of opioid-related claims may accomplish what government has not to date: holding entities and individuals accountable for direct harms to American users.
Border Security and Illegal Importation
High volumes of elicit and prescription opioids illegally imported into the U.S. from China, Mexico, and elsewhere are fueling the ongoing epidemic. On January 31, 2019, federal border agents in Arizona made the largest fentanyl bust in American history,22 preventing the street distribution of enough fentanyl to kill 52 million people in a single seizure. Emerging strategies to prevent illegal opioid importations focus on increased use of “cameras, sensors, drones and other smart technology” to address insufficiencies among border security measures.Reference Rockwell23 Large amounts of opioids also arrive each day through international mail services. On October 24, 2018, President Trump signed the STOP Act, a bipartisan effort requiring the U.S. Postal Service to share electronic data on all incoming international mail with U.S. Customs and Border Protection by the end of 2020.24
Profound impacts of opioid misuse among rural populations across the country stem from a ready supply of opioids coupled with a lack of public health infrastructure, workforce, and treatment services. From 1999-2015, the prevalence rate of drug overdose deaths in rural areas increased by 325% (as contrasted with 198% in urban areas).
Rural Access
Profound impacts of opioid misuse among rural populations across the country stem from a ready supply of opioids coupled with a lack of public health infrastructure, workforce, and treatment services. From 1999-2015, the prevalence rate of drug overdose deaths in rural areas increased by 325% (as contrasted with 198% in urban areas).25 Rural health professionals need greater authority to provide MAT, resources to recruit and retain qualified professionals through loan repayment programs, and reimbursements for telehealth and inpatient services. Qualified physicians, nurse practitioners, and physician assistants can provide MAT with government-issued waivers, but 60% of rural counties in 2016 lacked any waivered providers.Reference Andrilla26 Legal incentives are needed for rural health professionals to become telehealth treatment providers. States can also leverage Medicaid state plan amendments via Social Security Act waivers27 to set reimbursement schedules for OUD patients in inpatient programs.
Legal Aid Responses
Beyond their needs for medical treatment and mental health support services, persons suffering with OUD face a battery of legal issues related to their addictions. The opioid crisis has devastating impacts on families and communities. Users may be charged with multiple crimes (e.g., possession, theft, DUI, assault, vagrancy). They face social stigma-tization, job loss, and homelessness. Parents risk losing custody of their children. Others may fall victim to acts of domestic violence. Legal Services Corporation, a non-profit established by Congress, developed the Opioid Task Force (OTF) in 2018. OTF aligns an interdisciplinary team of legal, public health, social work, and other professionals to address the growing legal effects of the opioid crisis.28 Like medical-legal partnerships within hospitals nationally, OTF helps opioid abusers and their families navigate legal and practical challenges, including loss of housing, employment, and health care access. Additionally, it encourages holistic responses to the crisis by educating engaged professionals on issues facing persons with OUDs, promoting a “comprehensive model of recovery.”Reference Levi29
Over twenty years opioid addiction and misuse have caused hundreds of thousands of deaths and countless incidences of morbidity among Americans across the social spectrum. The resulting crisis is by far the nation's worst public health emergency. Meaningful governmental responses to date are well-intended but inadequate. Innovative legal responses are needed to effectively combat opioid misuse, tamp down mortality, and circumvent future harms. Addressing multiple factors underlying the opioid crisis in new ways can immediately decrease OUDs and prevent the victimization of another generation to an epidemic of addiction with no natural end.
